ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1586

The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Abstract Number: 2104

The Relationship of Soluble Biomarkers to OA Pain: A Systematic Literature Review
Abstract Number: 2291

The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease
Abstract Number: 0318

The Relevance of a Positive ANA in New Patient Referrals to Rheumatology
Abstract Number: 1685

The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Abstract Number: 1948

The Rheumatology Physician Assistant/Associate Workforce
Abstract Number: 2666

The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans
Abstract Number: 2264

The Risk of Malignancy and Major Adverse Cardiovascular Events with the Use of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Real-World Evidence
Abstract Number: 2117

The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260
Abstract Number: 0564

The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
Abstract Number: 0038

The Role of Dual Specificity Phosphatase 22 (DUSP22) in Rheumatoid Arthritis: Mechanism and Genetic Investigations
Abstract Number: 0686

The Role of Inflammation in Systemic Sclerosis: CRP-Associated Phenotypes and Prognostic Implications
Abstract Number: 2371

The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
Abstract Number: 1103

The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study
Abstract Number: 2059

The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].